FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+407.79%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$1.38B
AUM Growth
+$70.6M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
14
New
Increased
Reduced
Closed

Top Buys

1
+$224M
2
+$23.2M
3
+$3.37M

Top Sells

1
+$129M
2
+$127M
3
+$73.2M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$54.4M
5
ELVN icon
Enliven Therapeutics
ELVN
+$51.4M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DMRA
1
Damora Therapeutics
DMRA
$1.41B
$226M 16.3%
+8,713,000
DNTH icon
2
Dianthus Therapeutics
DNTH
$4.46B
$213M 15.38%
2,537,191
+400,000
COGT icon
3
Cogent Biosciences
COGT
$5.6B
$212M 15.3%
5,503,418
-3,500,000
SYRE icon
4
Spyre Therapeutics
SYRE
$6.01B
$203M 14.64%
4,018,101
ORKA
5
Oruka Therapeutics
ORKA
$3.33B
$182M 13.13%
3,705,262
VRDN icon
6
Viridian Therapeutics
VRDN
$1.75B
$76.6M 5.53%
3,914,458
ELVN icon
7
Enliven Therapeutics
ELVN
$2.16B
$72.7M 5.25%
1,855,644
-1,855,800
JBIO
8
Jade Biosciences
JBIO
$876M
$64M 4.62%
4,553,494
CBIO
9
Crescent Biopharma
CBIO
$469M
$50.5M 3.65%
2,747,866
ZBIO
10
Zenas BioPharma
ZBIO
$1.08B
$46.1M 3.33%
2,359,025
+150,000
APGE icon
11
Apogee Therapeutics
APGE
$5.93B
$25.1M 1.82%
298,647
-1,750,000
IKT icon
12
Inhibikase Therapeutics
IKT
$224M
$14.5M 1.05%
8,625,000
KNSA icon
13
Kiniksa Pharmaceuticals
KNSA
$3.61B
– –
-1,319,688
NUVL icon
14
Nuvalent
NUVL
$7.22B
– –
-727,563